Skip to content

Intrauterine Environment in Polycystic Ovary Syndrome (PCOS) Probands

Genes, Androgens and Intrauterine Environment in PCOS

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00364949
Enrollment
70
Registered
2006-08-16
Start date
2003-01-31
Completion date
2012-07-31
Last updated
2013-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Keywords

Polycystic Ovary Syndrome, PCOS, Pregnant, Cord Blood

Brief summary

Polycystic ovary syndrome (PCOS) is among the most common endocrine disorders in premenopausal women, affecting 7-10% of this population. This syndrome is characterized by elevated levels of testosterone and chronic anovulation, and frequently of obesity. This study is designed to test the hypothesis that there is in utero testosterone excess, altered insulin secretion, and/or intrauterine growth retardation in the female offspring of women with PCOS. The allele 8 can be used to identify the reproductive and metabolic abnormalities associated with PCOS. This study will determine whether allele 8 positive \[A8(+)\] female offspring have more profound changes in these parameters compared to A8(-) female offspring. Androgen and insulin levels in amniotic fluid from pregnant women with PCOS will be compared to levels in pregnant control women. Androgen and insulin levels in cord blood will also be measured. Further, gestational age and anthropomorphic measurements in offspring of women with PCOS will be assessed and compared to that in offspring of matched control women. We will test the hypothesis that androgens are elevated in infancy in the female offspring of women with PCOS. We will assess sex steroids, insulin, and c-peptide levels in infants of PCOS women and compare them to the levels in infants of control women up to 1 year of age during the minipuberty of infancy. We will determine whether any of these parameters differ in A8(+) compared to A8(-) PCOS offspring.

Detailed description

BACKGROUND Polycystic ovary syndrome (PCOS) is among the most common endocrine disorders in premenopausal women, affecting 7-10% of this population. This syndrome is characterized by hyperandrogenism, chronic anovulation and, frequently, obesity. Hyperandrogenemia seems to be a consistent reproductive phenotype in male relatives as well as female relatives of PCOS women. This phenotype appears to have a genetic basis in PCOS families and shows significant linkage and association with a marker locus on chromosome 19p in the region of the insulin receptor (allele 8 of D19S884.). This allele is also recently found to be associated with a metabolic phenotype in PCOS probands and their brothers, including increased post-challenge glucose levels, apparent defects in insulin secretion, especially in response to sulfonylurea, and accelerated weight gain with age (unpublished date). Therefore, allele 8 status in PCOS probands and their family members can identify the reproductive and metabolic abnormalities. Many epidemiologic studies showed a plausible link between low birth weight and chronic metabolic disorders manifested as hypertension, diabetes and obesity later in life, suggestive of an early fetal programming. There is evidence to support fetal origin of PCOS. Female rhesus monkeys that were exposed to excess androgen in utero, were born smaller for gestational age. These animals had many of the reproductive features of PCOS, including increased LH levels, irregular ovulation, polycystic ovaries and functional ovarian hyperandrogenism. Similarly, in retrospective cohort studies, girls with elevated adrenal androgen levels or with PCOS were significantly smaller for gestational age at birth than reproductively normal control girls, suggestive of a possible fetal origin for some features of PCOS in human studies. Molecular mechanism for fetal programming is not clearly understood, but permanent changes in gene expression caused early insult may be a factor. HYPOTHESIS These observations have led to a new hypothesis for the etiology of PCOS; genetic variation resulting in hyperandrogenemia leads to many of the reproductive and metabolic features of PCOS later in life. We will directly test the hypothesis that there is an excess androgen production in female offspring of women with PCOS. Further, we will test whether A8(+) female offspring have more profound changes in these parameters (increased androgen and/or decreased insulin levels in fetal life and in infancy) compared to A8(-) female offspring.

Interventions

None listed

Sponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Lead SponsorNIH

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
Yes

Inclusion criteria

Probands who meet the following criteria will be enrolled: Menses \< 6 per year without confounding meds Not taking confounding medications at the time of hormone analysis, willing to be off confounding medications for required washout period, or able to provide documentation of hyperandrogenemia (without hyperprolactinemia or evidence of non-classical adrenal hyperplasia) with past laboratory tests during a time when not taking confounding medications Total Testosterone \>58 ng/dl or bioavailable testosterone \>15 ng/dl Prolactin \<25 ng/ml Baseline 17-OHP \<3 ng/ml (and stimulated 17-OHP \<10 ng/ml if subject is studied on-site) Control women who meet the following criteria will be enrolled: History of completely regular menstrual cycles. No history of hirsutism or alopecia. Control women will have a blood sample obtained 3-6 months after they have stopped lactating and resumed regular menses to ensure that they have normal T, uT and DHEAS levels. Any pregnant woman who develops gestational diabetes will be excluded from the analysis. To exclude disorders associated with insulin resistance, control subjects will have no personal history of hypertension or hypertriglyceridemia and no first-degree relative with Type 2 DM

Exclusion criteria

* history of gestational diabetes mellitus, eclampsia, pre-eclampsia or any medical disorders complicating their pregnancies.

Design outcomes

Primary

MeasureTime frameDescription
Estradiol Level in Female OffspringOne time sampling from the cord bloodThe blood that were analyzed were taken from cord blood and not from the offspring.
Androstenedione Level in Female Offspringcord blood
Testosterone Level in Female Offspringcord blood
17-hydroxyprogesterone Level in Female Offspringcord blood
Dihydrotestosterone Level in Female Offspringcord blood
Dehydroepiandrosterone Level in Female Offspringcord blood
Infant Birth Weight (Male and Female)birth

Countries

United States

Participant flow

Recruitment details

letters to participants from other studies and patients from Ob/Gyn at Northwestern

Pre-assignment details

Exclusion based on personal/family history of diabetes or pre-existing medical condition

Participants by arm

ArmCount
Control
Control
31
PCOS
Polycystic Ovary Syndrome
39
Total70

Baseline characteristics

CharacteristicControlPCOSTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
31 Participants39 Participants70 Participants
Maternal age at delivery32.4 yr
STANDARD_DEVIATION 4.4
30.1 yr
STANDARD_DEVIATION 3.9
31.1 yr
STANDARD_DEVIATION 4
Pre-pregnancy BMI25.1 kg/m^2
STANDARD_DEVIATION 5.7
30.8 kg/m^2
STANDARD_DEVIATION 8.9
28.3 kg/m^2
STANDARD_DEVIATION 7.5
Region of Enrollment
United States
31 participants39 participants70 participants
Sex: Female, Male
Female
31 Participants39 Participants70 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 310 / 39
serious
Total, serious adverse events
0 / 310 / 39

Outcome results

Primary

17-hydroxyprogesterone Level in Female Offspring

Time frame: cord blood

Population: The number of participants analyzed only included the levels of the female offspring.

ArmMeasureValue (MEAN)Dispersion
Control17-hydroxyprogesterone Level in Female Offspring2990 ng/dlStandard Deviation 1883
PCOS17-hydroxyprogesterone Level in Female Offspring2777 ng/dlStandard Deviation 2103
p-value: 0.77t-test, 2 sided
Primary

Androstenedione Level in Female Offspring

Time frame: cord blood

Population: The number of participants analyzed only included the levels of the female offspring.

ArmMeasureValue (MEAN)Dispersion
ControlAndrostenedione Level in Female Offspring146 ng/dlStandard Deviation 104
PCOSAndrostenedione Level in Female Offspring87 ng/dlStandard Deviation 46
p-value: 0.042t-test, 2 sided
Primary

Dehydroepiandrosterone Level in Female Offspring

Time frame: cord blood

Population: The number of participants analyzed only included the levels of the female offspring.

ArmMeasureValue (MEAN)Dispersion
ControlDehydroepiandrosterone Level in Female Offspring5 ng/mlStandard Deviation 4
PCOSDehydroepiandrosterone Level in Female Offspring3 ng/mlStandard Deviation 2
Primary

Dihydrotestosterone Level in Female Offspring

Time frame: cord blood

Population: The number of participants analyzed only included the levels of the female offspring.

ArmMeasureValue (MEAN)Dispersion
ControlDihydrotestosterone Level in Female Offspring88 pg/mlStandard Deviation 75
PCOSDihydrotestosterone Level in Female Offspring137 pg/mlStandard Deviation 162
p-value: 0.325t-test, 2 sided
Primary

Estradiol Level in Female Offspring

The blood that were analyzed were taken from cord blood and not from the offspring.

Time frame: One time sampling from the cord blood

Population: The number of the participants analyzed only included the levels for the female offspring.

ArmMeasureValue (MEAN)Dispersion
ControlEstradiol Level in Female Offspring18606 pg/mlStandard Deviation 18845
PCOSEstradiol Level in Female Offspring6467 pg/mlStandard Deviation 3989
p-value: 0.049t-test, 2 sided
Primary

Infant Birth Weight (Male and Female)

Time frame: birth

Population: Birth weight of the male and female infants.

ArmMeasureValue (MEAN)Dispersion
ControlInfant Birth Weight (Male and Female)3571 gramStandard Deviation 389
PCOSInfant Birth Weight (Male and Female)3539 gramStandard Deviation 597
Primary

Testosterone Level in Female Offspring

Time frame: cord blood

Population: The number of participants analyzed only included the levels of the female offspring.

ArmMeasureValue (MEAN)Dispersion
ControlTestosterone Level in Female Offspring19 ng/dlStandard Deviation 29
PCOSTestosterone Level in Female Offspring7 ng/dlStandard Deviation 1
p-value: 0.156t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026